131 related articles for article (PubMed ID: 37952139)
21. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
22. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation.
Sanchez-Escamilla M; Flynn J; Devlin S; Maloy M; Fatmi SA; Tomas AA; Escribano-Serrat S; Ponce D; Sauter CS; Giralt SA; Scordo M; Perales MA
Bone Marrow Transplant; 2023 May; 58(5):498-505. PubMed ID: 36721042
[TBL] [Abstract][Full Text] [Related]
23. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Salas MQ; Eikema DJ; Koster L; Maertens J; Passweg J; Finke J; Broers AEC; Koc Y; Kröger N; Ozkurt ZN; Pascual-Cascon MJ; Platzbecker U; Van Gorkom G; Schroeder T; López-Lorenzo JL; Martino M; Chiusolo P; Kaufmann M; Onida F; Gurnari C; Scheid C; Drozd-Sokolowska J; Raj K; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Apr; 59(4):479-488. PubMed ID: 38253869
[TBL] [Abstract][Full Text] [Related]
24. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE
Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
Bourgeois AL; Jullien M; Garnier A; Peterlin P; Béné MC; Guillaume T; Chevallier P
Clin Transl Med; 2023 Apr; 13(4):e1242. PubMed ID: 37140099
[TBL] [Abstract][Full Text] [Related]
27. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era.
Yeh J; Whited L; Saliba RM; Rondon G; Banchs J; Shpall E; Champlin R; Popat U
Blood Adv; 2021 Dec; 5(24):5599-5607. PubMed ID: 34592759
[TBL] [Abstract][Full Text] [Related]
28. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
29. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
García-Cadenas I; Redondo S; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Oñate G; López J; Caballero AC; Miqueleiz S; Arguello-Tomas M; Briones J; Sierra J; Martino R
Transplant Cell Ther; 2023 Jul; 29(7):473.e1-473.e6. PubMed ID: 37086849
[TBL] [Abstract][Full Text] [Related]
30. EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide.
Mariotti J; Magri F; Giordano L; De Philippis C; Sarina B; Mannina D; Taurino D; Santoro A; Bramanti S
Bone Marrow Transplant; 2023 Mar; 58(3):247-256. PubMed ID: 36414698
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
[TBL] [Abstract][Full Text] [Related]
32. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.
Chhabra S; Jerkins JH; Monahan K; Szabo A; Shah NN; Abedin S; Runaas L; Fenske TS; Pasquini MC; Shaw BE; Drobyski WR; Saber W; D'Souza A; Dhakal B; Mohan M; Longo W; Hamadani M
Bone Marrow Transplant; 2024 Mar; 59(3):373-379. PubMed ID: 38177221
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
[TBL] [Abstract][Full Text] [Related]
34. Incidence and Role of Recipient-Specific Antibodies in Allogeneic Hematopoietic Cell Transplantation from Mismatched Related Donors.
Sadowska-Klasa A; Dukat-Mazurek A; Zielińska H; Dębska-Zielkowska J; Piekarska A; Moszkowska G; Mensah-Glanowska P; Zaucha JM
Transplant Cell Ther; 2024 Jan; 30(1):99.e1-99.e10. PubMed ID: 37875214
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
[TBL] [Abstract][Full Text] [Related]
36. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
Nakamae H
Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
[TBL] [Abstract][Full Text] [Related]
37. EASIX-1year and late mortality after allogeneic stem cell transplantation.
Kordelas L; Terzer T; Gooley T; Davis C; Sandmaier BM; Sorror M; Penack O; Schaeper NDE; Blau IW; Beelen D; Radujkovic A; Dreger P; Luft T
Blood Adv; 2023 Sep; 7(18):5374-5381. PubMed ID: 37477588
[TBL] [Abstract][Full Text] [Related]
38. EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation.
Tolosa-Ridao C; Cascos E; Rodríguez-Lobato LG; Pedraza A; Suárez-Lledó M; Charry P; Solano MT; Martinez-Sanchez J; Cid J; Lozano M; Rosiñol L; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Martínez C; Carreras E; Díaz-Ricart M; Rovira M; Salas MQ
Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38521885
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia.
Borovkova AS; Paina OV; Semenova EV; Bykova TA; Osipova AA; Slesarchuk OA; Kozhokar PV; Tsvetkova LA; Rakhmanova ZZ; Kozlov AV; Chukhlovin AB; Kazantsev IV; Estrina MA; Goloshchapov OV; Bondarenko SN; Moiseev IS; Kulagin AD; Zubarovskaya LS
Clin Transplant; 2024 Jan; 38(1):e15181. PubMed ID: 37922213
[TBL] [Abstract][Full Text] [Related]
40. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Mata JR; Zahurak M; Rosen N; DeZern AE; Jones RJ; Ambinder AJ
Transplant Cell Ther; 2024 Jun; 30(6):588-596. PubMed ID: 38521411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]